Have a personal or library account? Click to login
Association between serum uric acid level and non-alcoholic fatty liver disease in Koreans Cover

Association between serum uric acid level and non-alcoholic fatty liver disease in Koreans

Open Access
|Feb 2022

References

  1. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011; 140:124–31.
  2. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology. 2010; 51:1979–87.
  3. Bae JC, Cho YK, Lee WY, Seo HI, Rhee EJ, Park SE, et al. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol. 2010; 105:2389–95.
  4. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Prevalence and risk factors of non alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006; 21:138–43.
  5. Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M, Jalal DI. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism. 2013; 62:392–9.
  6. Lu Z-Y, Shao Z, Li Y-L, Wulasihan M, Chen X-H. Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: an 8-year follow-up study. World J Gastroenterol. 2016; 22:3663–9.
  7. Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Eng J Med. 2008; 359:1811–21.
  8. Lee JW, Cho YK, Ryan M, Kim H, Lee SW, Chang E, et al. Serum uric acid as a predictor for the development of nonalcoholic fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut Liver. 2010; 4:378–83.
  9. Ryu S, Chang Y, Zhang Y, Kim S-G, Cho J, Son HJ, et al. A cohort study of hyperuricemia in middle-aged South Korean men. Am J Epidemiol. 2012; 175:133–43.
  10. Petta S, Camma C, Cabibi D, Di Marco V, Craxì A. Hyperuricemia is associated with histological liver damage in patients with non alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011; 34:757–66.
  11. Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features. Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016; 46:1074–87.
  12. Sandra S, Lesmana CRA, Purnamasari D, Kurniawan J, Gani RA. Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) progression evaluated using controlled attenuation parameter-transient elastography: lesson learnt from tertiary referral center. Diabetes Metab Syndr. 2019; 13:424–8.
  13. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ. 2007; 85:867–72.
  14. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6:33. doi: 10.1186/1471-230X-6-33
  15. Hagström H, Nasr P, Ekstedt M, Stål P, Hultcrantz R, Kechagias S. Accuracy of noninvasive scoring systems in assessing risk of death and liver-related endpoints in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019; 17:1148–56.e4. doi: 10.1016/j.cgh.2018.11.030
  16. McPherson S, Hardy T, Dufour J-F, Petta S, Romero-Gomez M, Allison M, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017; 112:740–51.
  17. Grant EG. Liver. In: Mittelstaedt CA, editor. General ultrasound. New York: Churchill Livingstone; 1992, pp. 173–248.
  18. Li C, Hsieh M-C, Chang S-J. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013; 25:210–6.
  19. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67:328–57.
  20. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2013; 19:325–48.
  21. Fernández Rodríguez CM, Aller R, Gutiérrez García ML, Ampuero J, Gómez-Camarero J, Martín-Mateos RM, et al. Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD). Rev Esp Enferm Dig. 2019; 111:264–9. [in English]
  22. Jaruvongvanich V, Ahuja W, Wirunsawanya K, Wijarnpreecha K, Ungprasert P. Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017; 29:1031–5.
  23. Jaruvongvanich V, Ahuja W, Wijarnpreecha K, Ungprasert P. Hyperuricemia is not associated with severity of liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017; 29:694–7.
  24. Yoneda M, Thomas E, Sumida Y, Imajo K, Hyogo H, Fujii H, et al. Uric acid levels decrease with fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Biochem. 2014; 47:1138–9.
  25. Sertoglu E, Ercin CN, Celebi G, Gurel H, Kayadibi H, Genc H, et al. The relationship of serum uric acid with non-alcoholic fatty liver disease. Clin Biochem. 2014; 47:383–8.
  26. Ayonrinde OT, Olynyk JK, Beilin LJ, Mori TA, Pennell CE, de Klerk N, et al. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology. 2011; 53:800–9.
  27. Lanaspa MA, Sanchez-Lozada LG, Choi YJ, Cicerchi C, Kanbay M, Roncal-Jimenez CA, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem. 2012; 287:40732–44.
  28. Choi Y-J, Shin H-S, Choi HS, Park J-W, Jo I, Oh E-S, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest. 2014; 94:1114–25.
  29. Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram S, Le M, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013; 62:3307–15.
  30. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018; 68:305–15.
DOI: https://doi.org/10.2478/abm-2022-0003 | Journal eISSN: 1875-855X | Journal ISSN: 1905-7415
Language: English
Page range: 15 - 22
Published on: Feb 28, 2022
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year

© 2022 Huiyul Park, Kye-Yeung Park, Minki Kim, Hoon-Ki Park, Hwan-Sik Hwang, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution 4.0 License.